enow.com Web Search

  1. Ads

    related to: latest developments in schizophrenia and addiction recovery center

Search results

  1. Results from the WOW.Com Content Network
  2. FDA approves new type of schizophrenia drug - AOL

    www.aol.com/news/fda-approves-type-schizophrenia...

    The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

  3. FDA Approves the First New Schizophrenia Drug in Decades - AOL

    www.aol.com/fda-approves-first-schizophrenia...

    N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

  4. Soteria (psychiatric treatment) - Wikipedia

    en.wikipedia.org/wiki/Soteria_(psychiatric...

    [6] [12] Some also questioned the reported efficacy of the treatment, noting that Mosher's definition of patient recovery was staying off of drugs, with no assessment of their symptoms. [ 6 ] The US Soteria Project closed as a clinical program in 1983 due to lack of financial support, although it became the subject of research evaluation with ...

  5. The Institute of Living - Wikipedia

    en.wikipedia.org/wiki/The_Institute_of_Living

    The Institute of Living is a comprehensive psychiatric facility in Hartford, Connecticut, that offers care across the spectrum of psychiatric services, including crisis evaluation, [1] inpatient psychiatric care, [2] group homes, [3] [4] specialized educational programs, [5] outpatient programs, and addiction recovery services.

  6. Brilaroxazine - Wikipedia

    en.wikipedia.org/wiki/Brilaroxazine

    RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...

  7. Schizophrenia In America - The Huffington Post

    highline.huffingtonpost.com/articles/en/stop-the...

    And while antipsychotics can help schizophrenia’s “positive” symptoms, such as hallucinations, they have a minimal impact on the “negative” symptoms, which are arguably more devastating. People who have schizophrenia can lose the ability to focus, to sustain effort, to carry on a conversation or to maintain eye contact.

  1. Ads

    related to: latest developments in schizophrenia and addiction recovery center